Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
AIDS No Longer Among Top Ten Causes Of Death In NYC

For the first time since the HIV epidemic exploded more than a generation ago, AIDS is no longer one of the top 10 causes of death in New York City.

Published
14 March 2014
From
New York Daily News
Heart attack link to abacavir persists in D:A:D study

The nucleoside (NRTI) drug abacavir (Ziagen also in Kivexa/Epzicom) continues to be associated with a near-doubling of the risk of a heart attack, according to the latest

Published
14 March 2014
By
Gus Cairns
Can Gilead Dominate The HIV Drug Market Again in 2014?

The development of combination therapies provides Gilead with a long-lasting HIV product portfolio that should allow the company to maintain its leadership for the foreseeable future. As a result, Gilead is able to reinvest in its product portfolio.

Published
13 March 2014
From
Motley Fool
Efavirenz-based ART matches lopinavir/ritonavir for perinatal HIV treatment

Pregnant women taking efavirenz-based antiretroviral therapy had significantly better virologic outcomes at the time of delivery compared to those taking lopinavir/ritonavir in a randomised study in rural

Published
12 March 2014
By
Carole Leach-Lemens
New NNRTI doravirine matches efavirenz for first-line HIV treatment

The next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine (formerly MK-1439) showed potent antiretroviral activity and good tolerability in combination with tenofovir/FTC (the drugs in Truvada) in a dose-finding

Published
11 March 2014
By
Liz Highleyman
Heart attack risk in people with HIV may be falling – but not in women

A number of studies at last week’s Conference on Retroviruses and Opportunistic Infections (CROI) examined whether people with HIV had an elevated risk of heart attack and

Published
10 March 2014
By
Gus Cairns
Viral load rebounds in 35% of people using PI/r monotherapy: results of five-year PIVOT study

A long-term strategy study sponsored by the Medical Research Council (MRC) in the UK reported low rates of serious complications and the potential to reduce drug costs. However, more than a third of people on the PI/r monotherapy group had viral load rebound compared to only 3% of people on standard combination therapy.

Published
10 March 2014
From
HIV i-Base
Reports of a Second Baby Possibly Cured of HIV: Uncertainty Remains

The media is awash with stories relating to a conference presentation by Deborah Persaud from Johns Hopkins University, in which she described the case of an HIV-infected baby who was treated within four hours of birth and now shows no detectable HIV after nine months of follow up.

Published
10 March 2014
From
TAG Basic Science Blog
Novel two-drug maintenance combination works at least as well as triple therapy: stage set for long-lasting injectable formulation

An oral combination therapy of two antiretroviral drugs, the non-nucleoside rilpivirine (Edurant, also in Eviplera/Complera) and the new integrase inhibitor GSK1265744 (744), was at least as effective as

Published
08 March 2014
By
Gus Cairns
Protected T-cells persist and proliferate in HIV gene therapy study

Genetically modified CD4 T-cells lacking CCR5 co-receptors reach high levels in the body and are resistant to HIV infection, potentially enabling people to maintain a low viral

Published
07 March 2014
By
Liz Highleyman

Filter by country